Joseph E. Gilliam Sells 59,801 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 59,801 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $100.47, for a total transaction of $6,008,206.47. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares in the company, valued at $10,232,367.15. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Glaukos Trading Down 0.5 %

Shares of GKOS stock opened at $99.26 on Friday. The firm has a market cap of $4.91 billion, a P/E ratio of -35.71 and a beta of 1.08. Glaukos Co. has a 1-year low of $45.38 and a 1-year high of $102.33. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.34 and a quick ratio of 4.78. The firm’s 50-day simple moving average is $91.53 and its 200-day simple moving average is $79.84.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.07). The company had revenue of $82.40 million for the quarter, compared to analysts’ expectations of $81.00 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The company’s revenue was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.53) earnings per share. As a group, equities analysts forecast that Glaukos Co. will post -2.18 EPS for the current year.

Analyst Upgrades and Downgrades

GKOS has been the topic of a number of research reports. Mizuho increased their price objective on shares of Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday. Piper Sandler increased their price objective on shares of Glaukos from $90.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, December 22nd. Truist Financial reissued a “buy” rating and issued a $110.00 price objective on shares of Glaukos in a research note on Monday. JPMorgan Chase & Co. upgraded shares of Glaukos from a “neutral” rating to an “overweight” rating and upped their target price for the company from $66.00 to $91.00 in a report on Thursday, December 21st. Finally, Wells Fargo & Company upped their target price on shares of Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and an average target price of $99.80.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Xponance Inc. lifted its holdings in shares of Glaukos by 4.1% during the 4th quarter. Xponance Inc. now owns 2,879 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 113 shares during the period. Corient Private Wealth LLC increased its position in Glaukos by 0.7% during the 4th quarter. Corient Private Wealth LLC now owns 24,775 shares of the medical instruments supplier’s stock worth $1,969,000 after purchasing an additional 163 shares in the last quarter. Profund Advisors LLC increased its position in Glaukos by 6.4% during the 4th quarter. Profund Advisors LLC now owns 2,879 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 173 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Glaukos by 4.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the medical instruments supplier’s stock worth $310,000 after purchasing an additional 200 shares in the last quarter. Finally, American Century Companies Inc. increased its position in Glaukos by 3.1% during the 1st quarter. American Century Companies Inc. now owns 6,878 shares of the medical instruments supplier’s stock worth $339,000 after purchasing an additional 207 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.